Blood Products That Improve INR
For patients with elevated INR requiring urgent reversal, prothrombin complex concentrate (PCC) combined with intravenous vitamin K 10 mg is the preferred treatment, as it normalizes INR within 15 minutes compared to hours with fresh frozen plasma. 1
Primary Reversal Agents
Prothrombin Complex Concentrate (PCC) - First-Line Choice
PCC is superior to fresh frozen plasma for INR correction because it:
- Normalizes INR within 15 minutes of administration 2
- Contains 25 times higher concentration of clotting factors than FFP 3
- Requires no cross-match and minimal volume (infused in 10-15 minutes) 4, 3
- Is virally inactivated with lower risk of volume overload 4
Dosing is weight-based and INR-dependent 1:
- INR 2.0-3.9: 25 IU/kg
- INR 4.0-5.9: 35 IU/kg
- INR ≥6.0: 50 IU/kg
Four-factor PCC is preferred over three-factor PCC due to more successful INR reversal with fewer adverse events 5. Four-factor products contain adequate levels of factors II, VII, IX, and X plus proteins C and S 4.
Critical monitoring: Recheck INR 15-60 minutes after PCC administration, then every 6-8 hours for 24-48 hours. If INR remains ≥1.4 after initial PCC dosing, consider additional FFP 1.
Fresh Frozen Plasma (FFP) - Alternative When PCC Unavailable
FFP should be used only if PCC is not available 1. When FFP is necessary:
- Dose: 10-15 mL/kg IV 1, 6
- Always combine with vitamin K 10 mg IV 1
- Requires cross-match and prolonged thawing/administration time 4
- Takes hours (not minutes) to correct INR 7
Major limitations of FFP:
- Risk of transfusion-related acute lung injury (leading cause of transfusion-related mortality) 3
- Transfusion-associated circulatory overload (5-15% mortality rate) 3
- Allergic/anaphylactic reactions 3
- Volume overload, especially problematic in elderly patients 7
Vitamin K - Essential Adjunct
Vitamin K 10 mg IV must be given with either PCC or FFP to maintain reversal effect, as the half-life of infused coagulation factors is short (4-6 hours) while warfarin's anticoagulant effect is prolonged 5, 4.
- IV vitamin K begins reducing INR within 2 hours 4
- Full correction to normal range typically achieved within 24 hours 4
- Mix in minimum 50 mL IV fluid and infuse over minimum 20 minutes to minimize anaphylactoid reactions (risk ~3 per 10,000 doses) 4
Clinical Context Matters
Life-Threatening Bleeding (Intracranial Hemorrhage)
For warfarin-associated intracranial hemorrhage with INR ≥1.4: Vitamin K 10 mg IV plus 3- or 4-factor PCC (weight and INR-based dosing) is strongly recommended 1. This is critical because:
- 30-40% of intracranial hemorrhages expand within first 12-36 hours 2
- Expansion is prolonged with anticoagulation 2
- Elevated INR correlates with larger hematoma volumes 2
One study showed PCC reduced ICH progression from 44.2% to 17.2% compared to FFP alone 8.
Massive Hemorrhage
Early FFP infusion prevents dilutional coagulopathy during massive hemorrhage 9. Standard FFP dose of 15 mL/kg may be inadequate; larger volumes are often required 9.
Target fibrinogen >1.5 g/L (levels below 1 g/L are insufficient) 9. Fibrinogen is more sensitive than PT/INR for detecting developing coagulopathy 9.
Products That Do NOT Improve INR
Recombinant factor VIIa (rFVIIa) is NOT recommended for vitamin K antagonist reversal - strong recommendation against its use due to low quality evidence and thrombotic risk 1.
Platelet transfusions do not correct INR - they address platelet dysfunction/thrombocytopenia, not coagulation factor deficiency 9.
Cryoprecipitate does not correct INR - it provides fibrinogen and factor VIII but not the vitamin K-dependent factors (II, VII, IX, X) needed for INR correction 1.
Common Pitfalls
Avoid prophylactic plasma transfusion for mildly elevated INR without bleeding. Research shows most ICU patients with elevated INR have vitamin K deficiency (correctable with vitamin K alone) or liver disease (where plasma is inappropriate) 10. One institution reduced FFP use by 80% without increased bleeding by restricting transfusion to INR ≥2.0 in absence of active bleeding 11.
Do not use PCC routinely in cirrhosis patients not on vitamin K antagonists - it shows exaggerated procoagulant response and increased thrombotic risk in this population 3.
Beware of repeat PCC dosing - increases thrombotic complications and DIC risk 1.